The field of rheumatology has advanced rapidly as research continually alters standards of care for patients and increase the number of therapeutic options available for clinicians. A number of highly specialised laboratory and imaging techniques have been developed to better assess patients, both in terms of diagnosis, disease monitoring and predicting outcome. Perhaps most importantly of all, several targeted therapies including biological agents and small-molecule therapies have been licenced to manage these historically difficult to treat conditions. Allied with these novel pharmacological therapies, there have been advances in patient support, education and multidisciplinary care in order to manage these complex multi-faceted group of diseases.
Patients are increasingly demanding uniform access to the expert care they deserve. Following the success of the Eastern SpA Academy formed in 2017, the London (2019), Scotland (2020), Midlands (2021) and Physiotherapy (2021) and RA (2021) Academies were established to raise clinical standards, promote multidisciplinary care, and generate research interest. We hope to provide an overarching strategy for rheumatology learning, with central co-ordination to cover the wide breadth of topics relevant to practitioners managing rheumatological conditions, and to avoid repetition of topics and presentations.
During 2021, our inaugural RA Academy will be held at the Royal Society of Medicine, London. This hybrid 2-day event will be delivered by an internationally renowned faculty of leading experts. Each day has a theme and will cover topics pertinent to the care of patients with RA including presentation and care pathways; clinical assessment; imaging and case studies; pharmacological and non-pharmacological management. Due to the Covid-19 pandemic, many of our recent meetings have been virtual. However, we are delighted to re-establish face to meetings providing government guidance indicates that it is safe to do so. Continuing Professional Development (CPD) credits will be available for each event.
Please see the Events section of the website for further information.
Other doctors (general practitioners, musculoskeletal radiologists, Orthopaedic surgeons, ophthalmologists, dermatologists, gastroenterologists and others)
Rheumatology Nurses (specialist clinical nurse and research nurses)
Occupational therapists and orthotists
Please register for upcoming events by using the ‘Events’ tab above
Professor Karl Gaffney - MBBChBAO(Hons) FRCPI FRCP
Consultant Rheumatologist, Norfolk & Norwich University Hospital
Professor Karl Gaffney (MB, BCh, BAO Hons, FRCPI, FRCP) has been a Consultant Rheumatologist in Norwich since 1995 where he is service lead for axial
spondyloarthritis (including ankylosing spondylitis), adolescent rheumatology and osteoporosis. He is an Honorary Professor at Norwich Medical School, chair of the medical advisory board, National Axial Spondyloarthritis Society (www.nass.co.uk), founder member, treasurer and chair-elect of BRITSpA www.britspa.co.uk), chair of the British Society for Rheumatology (BSR) axial SpA Biologics Guidelines Committee, member of the National Early Inflammatory Arthritis Project Working Group, vice-chair of the BSR Heberden Committee, co-director and founder of the East of England and London Spondyloarthritis Academy (www.rheumatologyevents.org), and an invited member of the Assessment of Spondyloarthritis International Society www.asas-group.org.
He has also represented the BSR and NASS at the National Institute for Health and Care Excellence (NICE) appraisal of biological therapies since 2007. He was Rheumatology Service Director from 2008 until 2016, Director of Postgraduate Education in Norwich between 1999 and 2005, and Director of Rheumatology Training, Eastern Deanery between 2001 and 2007.
With NASS he has co-developed primary and secondary care educational programmes for healthcare professionals. These initiatives have been awarded national and European awards for excellence in healthcare communication. He is leading the NASS National Gold Standard Delay to Diagnosis project, launched at the House of Commons in July 2020 www.nass.co.uk/get-involved/gold-standard. His current research interests include epidemiology, dose optimisation and extra-articular manifestations of axial SpA. He oversees a large clinical trials programme and collaborates with other national and international centres. He has published extensively and has been an invited speaker at national and international meetings.
Consultant Rheumatologist, Cambridge University Hospitals
Dr Deepak Jadon is a consultant rheumatologist, Director of the Rheumatology Research Unit, and lead for psoriatic arthritis (PsA) at Addenbrooke’s Hospital, Cambridge.
Having grown up in Cardiff, he graduated from the University of Wales College of Medicine in 2003, and then undertook clinical training in rheumatology and general internal medicine in Bath and Bristol between 2007-2015. He completed his PhD thesis on ‘biomarkers of psoriatic arthritis phenotypes’ at the Royal National Hospital for Rheumatic Diseases (Bath, UK) in 2015.
Deepak has particular expertise in the investigation and management of psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA) and rheumatoid arthritis (RA). He is qualified in the use of musculoskeletal ultrasound.
Deepak is Director of the Rheumatology Research Unit at Cambridge University Hospitals NHSFT (Addenbrooke’s Hospital), where he leads a team of 5 research nurses, 3 rheumatology fellows, and 2 administrators. They are currently performing >20 clinical trials / studies of novel cutting-edge medications for the treatment of arthritis and other rheumatological diseases.
He is an Associate Principal Investigator in the Department of Medicine at the University of Cambridge. His research interests include genetic and serum biomarkers of PsA, AS and SpA, in particular those that predict prognosis.
Deepak is Theme Lead for E-learning at the University of Cambridge Clinical School, delivering high quality online learning to year 4-6 medical student.